Studies about the combination of radiotherapy, hyperthermia, and a radiosensitizer
| Project/Area Number |
22791208
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
TAKAGI Masaru 札幌医科大学, 医学部, 特任助教 (10404716)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 放射線治療生物学 / 放射線治療 / 抗癌剤 / 増感剤 / 温熱 |
|---|
| Research Abstract |
Gimeracil is a component of TS-1, an anti-cancer drug. Gimeracil enhanced cell-killing effects of camptothecin(CPT), 5-Fluorouracil(5-FU), and hydroxyurea. Combination of Gimeracil and CPT or 5-FU sensitized radiation more effectively than each modality alone. Gimeracil also enhanced heat sensitivity at 42℃or more. Combination of Gimeracil and heat sensitized radiation more than each modality alone did.
|
Report
(3 results)
Research Products
(4 results)
-
-
[Journal Article] Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination2011
Author(s)
Sakata K, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M, Fukushima M
-
Journal Title
Cancer Sci
Volume: 102(9)
Pages: 1712-1716
NAID
Related Report
Peer Reviewed
-
-
